Patent 8658385 was granted and assigned to Biosceptre International Limited on February, 2014 by the United States Patent and Trademark Office.
The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to anti-bodies for the diagnosis or condition, especially cancer.